SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
Millennium Pharmaceuticals, Inc. (MLNM)
An SI Board Since February 1997
Posts SubjectMarks Bans Symbol
3044 135 0 MLNM
Emcee:  icanpickem Type:  Unmoderated
Introduction Market Data Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
2644MILLENNIUM PHARMACEUTICALS (MLNM)-HOLD/SPECULATIVE (2S) [Citibank - Yaron WerberIcebrg-4/20/2006
2643[Inhibition of p38alpha MAPK enhances proteasome inhibitor-induced apoptosis of tuck-4/20/2006
2642Millennium and Johnson & Johnson Pharmaceutical Research and Development IniIan@SI-4/18/2006
2641Bortezomib Therapy in Patients With Relapsed or Refractory Lymphoma: Potential CIcebrg-4/12/2006
2640Crucell announces STAR(TM) Research License Agreement Leiden, The Netherlands, Icebrg-4/6/2006
2639PiperJaffary on CELG /Velcade /REVLIMID ---------------------------- ...VelcadeMLNM00-4/6/2006
2638Velcade sales - -------------------------------- No acceleration seen in spite MLNM00-3/29/2006
2637[Velcade & Herceptin versus breast cancer] >> Anticancer Drugs. 2006 tuck-3/23/2006
2636We had a potentially interesting Form 4 filing today. Raju Kucherlapati, who I bIcebrg-3/22/2006
2635CuraGen and TopoTarget Initiate Phase Ib/II Clinical Trial with PXD101 and VelcaIcebrg-3/22/2006
2634[Differential cellular and molecular effects of Velcade in human breast cancer ctuck-3/21/2006
2633Nitromed says CEO, CFO resigns Tue Mar 21, 2006 7:28 AM ET March 21 (Reuters) -Icebrg-3/21/2006
2632 >>Thromb Haemost. 2006 Jan;95(1):166-73. Treatment of embolic stroke intuck-3/20/2006
2631[Bortezomib modulates TLR4-induced dendritic cell activation] >>Blood. 20tuck-3/17/2006
2630Deleted, sorrytuck-3/17/2006
2629Millennium and Johnson & Johnson Pharmaceutical Research & Development IIcebrg-3/6/2006
2628The panel also agreed that the approval of Revlimid and increased marketing foculamamakara-3/2/2006
2627posts with nothing other than an opinion don't wash here at SI biotech. plescaram(o)uche-3/1/2006
2626recent downgrades shouldn't hurt MLNMkung-fu-trader-3/1/2006
2625A YMB poster put up the whole report: finance.messages.yahoo.com Makes things tuck-2/28/2006
2624P Morgan Cuts Millennium Pharm To Underweight >MLNM Tuesday, February 28, 20Icebrg-2/28/2006
2623WS Journal - Cardiac Pretreatment Is Challenged Studies Say Clot-Busters Before Icebrg-2/28/2006
2622Dr. Hans Black of InterInvest, Guest Market Monitor on Friday's Nightly BusiD.Lu-2/27/2006
2621Thank You for your post. My wife is going into clinical testing using cep701,atdw1963-2/25/2006
2620Campaigning in the Congo By Sarah Menesale/ News Staff Writer Friday, February 2Icebrg-2/25/2006
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News